Cracking Japanese drug development: A view from the inside

This white paper from Fulcrum Pharma Developments Inc. features an interview with Teruyoshi Okuda, president of Fulcrum Pharma Developments KK, the company's Japanese branch office. The Japanese market has always been difficult to access from the West due to differences in culture, medical approaches and regulatory requirements, as well as language and time zones. However, drug development in the East is changing. With the right approach, Western companies can succeed -- the key is choosing the right people on the ground.

"There have been dramatic changes in the Japanese system of drug development, from the conservative, traditional methods to a much more modern approach as seen in the West," says Mr. Okuda, who has a unique qualification to observe the differences between Eastern and Western drug development programs and comment on how they can be integrated.

• Email This Page
• Print This Page